Immunic, Inc.
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
Nasdaq: IMUX
IR Website: https://ir.imux.com/ir-home
Headquarters: New York, NY
Content provided by Immunic, Inc. on 3-3-22.
TALK TO MANAGEMENT
The Immunic, Inc. management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products:
Lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis.
IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome.
IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Investor Presentation
Recent News
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity
Feb 24, 2022
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis
Feb 18, 2022
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
Feb 17, 2022
Immunic, Inc. to Participate in Investor and Scientific Conferences in February
Feb 8, 2022
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Feb 2, 2022
Management Overview
Dr. Daniel Vitt
Chief Executive Officer, President and Director
Daniel Vitt, Ph.D., joined Immunic in January 2017, and subsequent to the company’s reverse takeover transaction with Vital Therapies in 2019, has served as Chief Executive Officer, President and Director of Immunic, Inc. Previously, he was Chief Scientific Officer and Chief Development Officer of 4SC AG, a publicly traded company based in Germany that he co-founded in 1997. While there, he successfully grew the company from the research stage into an advanced therapeutic development company with several clinical-stage product candidates in the pipeline.
Dr. Vitt studied chemistry in Siegen and Würzburg, Germany, and graduated from the University of Würzburg, where he focused on quantum-chemical calculations of organic reactions. He received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg, where he focused on molecular design of small molecule therapeutics.
Dr. Vitt is currently a member of the advisory board of the venture capital fund “Wachstumsfond Bayern 2,” managed by Bayern Kapital GmbH. In 2018, he also co-founded Brauhaus Germering GmbH, a local German specialty brewery.
Dr. Hella Kohlhof
Chief Scientific Officer
Hella Kohlhof, Ph.D., joined Immunic in January 2017 as Chief Scientific Officer, where she is responsible for the company’s scientific strategy, including mode of action studies, preclinical studies and biomarker development. Dr. Kohlhof also serves as Managing Director of Immunic’s research subsidiary, Immunic Research GmbH, Halle (Saale). She brings to Immunic a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology.
In 2008, Dr. Kohlhof joined 4SC AG as scientific group leader and worked on preclinical and clinical stage projects, including IMU-838 and IMU-935. During this time, she held several positions, including Director of Development Projects, where she was responsible for the entire product development pipeline of 4SC.
Dr. Kohlhof studied biology in Aachen and Munich, Germany, and Gothenburg, Sweden. She received her doctorate in biology from the Ludwig Maximilians University of Munich and the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, where she worked on normal and malignant B cell development, influenced by Notch and Epstein Barr Virus mediated signaling, and where she also performed her post doctorate work.
Dr. Kohlhof has been awarded several patents and is co-author of several scientific publications. She is a frequent guest speaker at scientific and industry conferences.
Dr. Andreas Muehler
Chief Medical Officer
Andreas Muehler, M.D., M.B.A., joined Immunic in August 2016. He has more than 25 years of leadership experience in the U.S. and European pharmaceutical industry, with an emphasis on preclinical and clinical development, business development and licensing, private equity, as well as medical affairs marketing.
From 2009 until joining Immunic, Dr. Muehler was an independent medical consultant, working on assignments in the U.S. and in Germany. During this time, he served in key interim leadership roles at a number of pharmaceutical and medical device companies.
Earlier in his career, he served at the helm of several U.S. based companies. Specifically, Dr. Muehler was President and Chief Executive Officer of medical device company, MicroMRI, Inc., and President of medical device company, CAD Sciences, which he subsequently sold to iCAD Medical in 2006. Dr. Muehler also served as Chief Executive Officer and Vice President, Corporate Development at the biotech company Cellectar Inc. Before that, Dr. Muehler served in a number of key positions at the mid-sized, U.S.-based pharmaceutical company Berlex Laboratories, where his roles spanned preclinical and clinical development, business development, as well as licensing and marketing. Before joining the industry, Dr. Muehler focused on academic research at the University of California, San Francisco.
Dr. Muehler received an M.D. from Humboldt-University (Charité) in Berlin, Germany, and an M.B.A. from Duke University in Durham, North Carolina. Dr. Muehler has served on the Board of Directors of multiple emerging medical technology companies, is the co-inventor of more than 25 patents and is the author or co-author of more than 90 publications in peer-reviewed journals.
Patrick Walsh
Chief Business Officer
Mr. Walsh joined Immunic from Akebia Therapeutics, Inc., where he served as Vice President of Business Development and completed an array of strategic transactions, including multiple partnerships, in-licenses, non-dilutive financings, and a merger. Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development. Earlier in his career, he was a consultant to life science companies with Capgemini SE and was on the healthcare investment banking team at Leerink Partners (now SVB Leerink).
Mr. Walsh holds both an M.S. in molecular, cellular and developmental biology and an MBA from the University of Michigan and a B.A. in biology and economics from Colby College.
Inderpal Singh
General Counsel
Mr. Singh joined Immunic from Sandoz International GmbH, where he served as the Global Legal Head of Biopharma since January 2018. During his tenure at Sandoz and as a member of various leadership teams, he was responsible for all legal activities, including development, regulatory, and medical matters, as well as commercial operations, business development, alliance management and market access for biopharma. Before that, from 2015 through 2017, Mr. Singh served at Merck KGaA as Global Legal Head of Global Manufacturing and Supply and Regional Counsel of Middle East and Africa, Commonwealth of Independent States and Turkey. From 2013 to 2015, he was Legal Director (Europe) at Biogen Idec International GmbH. Earlier in his career, Mr. Singh spent 15 years in legal positions of increasing responsibility at Pfizer Deutschland GmbH and Pfizer Inc. (U.S.).
After earning his college degree in India, Mr. Singh qualified as an attorney with specialization in Corporate and Commercial Law at Johannes-Gutenberg University in Mainz, Germany. He also completed two executive MBA programs at the University of Mannheim, Germany and INSEAD Business School in Fontainebleau, France.
Glenn Whaley, CPA
Vice President - Finance, Principal Financial and Accounting Officer
Glenn Whaley, CPA, joined Immunic as Principal Accounting Officer and Controller in December 2019. In April 2020, he was promoted to the position of Vice President Finance, Principal Financial and Accounting Officer. Mr. Whaley brings to Immunic more than 30 years of experience in accounting and finance.
Prior to joining Immunic, from March 2015 until May 2019, Mr. Whaley held roles of increasing responsibility at specialty pharmaceuticals company, Pernix Therapeutics, most recently serving as Vice President of Finance. Previously, Mr. Whaley was Vice President of Finance for Alvogen, Inc, a global pharmaceutical company; Corporate Controller for ImClone Systems, a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology; and served in various, key financial roles in public accounting and in the pharmaceutical and telecommunications industries.
Mr. Whaley earned a Bachelor of Science degree from Rutgers University Business School and is a Member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
Dr. Duane Nash
Executive Chairman
Duane Nash, M.D., J.D., M.B.A, joined Immunic’s board as its chairman in 2019. Since April 2020, he has temporarily assumed the role of Executive Chairman.
From 2012 to 2019, Dr. Nash served in various leadership roles at Vital Therapies (Nasdaq: VTL), most recently as its Chief Executive Officer. Additional roles included Medical Director, Executive Vice President, Chief Business Officer and President. Prior to joining Vital Therapies, Dr. Nash held various positions at Wedbush PacGrowth Life Sciences, an investment bank, where he worked from 2009 to 2012, most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, which was acquired by Wedbush in 2009.
Dr. Nash also practiced law from 2002 to 2008, most recently at the law firm of Davis Polk & Wardwell, where he focused on intellectual property litigation and corporate matters. Dr. Nash served on the board of directors of Aerpio Pharmaceuticals (Nasdaq: ARPO) from 2012 to 2017, and Akebia Therapeutics (Nasdaq: AKBA) from 2013 to 2018.
Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California, San Francisco.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Immunic Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
